Your Global Leader in Stem Cell Market Research
Human cell experts from Germany’s  CO.DON AG are again cutting the edge: they have launched human cells production on an industrial scale. The demanding quality standards required of the manufacturing conditions for human cell transplants led to the development of Integrated Isolator Technology (IIT) alongside industrial partners, which went into operation at CO.DON´s Teltow site in 1999. [Read more…]
HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]
San Antonio, Texas, May 06, 2025 – BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, has unveiled the first vehicle of its kind in the world, a mobile leukapheresis center designed to perform leukapheresis collections of starting materials for cell and gene therapies.
In a bold move that has consolidated the landscape of advanced therapy manufacturing, Altaris LLC announced the successful acquisition of two key cell and gene therapy operations—Advanced Therapies U.S. and OXGENE—from WuXi AppTec. Completed on March 7, 2025, the transaction marks a strategic expansion of Altaris’ footprint in the fast-growing cell and gene therapy contract development and manufacturing organization (CDMO) space. [Read more…]
TOKYO – Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.
This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics. Drug developers can leverage RoosterBio’s technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi’s GCTP*1/GMP*2 facility designed specifically for cell therapies. [Read more…]
